KROS 102
Alternative Names: KROS-102Latest Information Update: 16 Mar 2022
At a glance
- Originator Cedars-Sinai Medical Center
- Developer Kairos Pharma
- Class Small molecules
- Mechanism of Action Glucocorticoid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 23 Feb 2022 Kairos Pharma has patent protection for KROS 102 (Kairos Pharma website, February 2022)
- 01 Dec 2021 Early research in Autoimmune disorders in USA (unspecified route), prior to December 2021 (Kairos Pharma website, February 2022)
- 01 Dec 2021 Preclinical trials in Autoimmune disorders in USA (unspecified route), prior to December 2021 (Kairos Pharma website, February 2022)